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Purpose/Objective: To evaluate the impact of clinical and 
dosimetric risk factors on acute gastrointestinal (GI) and 
genitourinary (GU) toxicity during hypofractionated intensity-
modulated radiotherapy (IMRT) in patients with prostate 
cancer. 
Materials and Methods: Between May 2009 and August 2014, 
195 patients with prostate cancer and negative lymph nodes 
underwent IMRT. Median age was 74 years (range 57-85). 
Disease stage: T1a in 3 patients (1.54%), T1b in 2 (1.03%), 
T1c in 28 (14.36%), T2a in 21 (10.77%), T2b in 36 (18.46%), 
T2c in 83 (42.56%), T3a in 9 (4.62%), T3b in 13 (6.67%); 
Gleason scores were 2- 6 in 114 patients (58.47 %),7 in 55 
(28.21 %) and 8-10 in 26 (13.34%). Median basal PSA was 8.1 
ng/ml (range 1.6-42.59 ng/ml). 107/195 patients (54.87%) 
received hormonal therapy (LHRH analogue and/or 
antiandrogen). IMRT was delivered with 15 MV photons. 
Planning target volume (PTV) consisted of CTV plus 1 cm in 
all directions except at the prostate-rectal interface where 
the margin was 0.5 cm. A hypofractionated regimen delivered 
a prescribed dose of 74.25 Gy in 33 fractions (2.25 
Gy/fraction) to the prostate and, if involved, to the seminal 
vescicles (SV). When the risk of SV involvement was >15% 
according Roach’s formula SV received 62 Gy in 33 fractions 
(1.879 Gy/fraction) using a simultaneous integrated boost 
(SIB-IMRT) . Median prostate volume was 43.93 cm3 (range 
16.72-161.60 cm3). Acute toxicity was scored using Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0.  
Results: At median follow-up of 26 months (range 3-60) acute 
genitourinary (GU) toxicity was observed in 140 (71.80%) 
patients: G1 in 81 (41.54%), G2 in 49 (25.13%), G3 in 10 
(5.13%). Acute gastrointestinal (GI) toxicity, consisting mainly 
of proctitis, was observed in 79 (40.51%) patients: G1 in 44 
(22.56%), G2 in 33 patients (16.92 %), G3 in 2 patients 
(1.03%). There was no G4 acute GU or GI toxicity. 
Administration of 3-OH-Methylglutaryl CoA reductase 
inhibitors (statins) significantly reduced the GI toxicity rate 
and grade (p =0.028 and p =0.029 respectively; Chi-Square 
test). Large prostate volume was associated with a higher 
rate and grade of acute GU toxicity (p = 0.02 Mann-Whitney 
test and p = 0.003 Spearman’s correlation). Bladder V50 
correlated with a higher grade of acute GU toxicity (p =0.038 
Spearman’s correlation) . GU and GI toxicities rate and grade 
were strongly interrelated (p =0.000; Chi-Square test). 
Conclusions: Hypofractionated IMRT for prostate cancer is 
safe and is associated with low acute toxicities. A large pre-
treatment prostate volume was associated with increased GU 
toxicity. We hypothesized that statins use might lower the 
incidence of GI toxicity. During treatment planning bladder 
V50 should be reduced in order to avoid GU toxicity. 
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Purpose/Objective: To study bladder filling in patients 
receiving external beam radiotherapy (EBRT) for 
gynaecological cancer and its impact on target coverage. 
Cervical and endometrial cancers are the most common 
gynaecological cancers treated with EBRT. At radiotherapy 
planning we aim for a ‘comfortably full bladder’in an attempt 
to move small bowel out of the pelvis and thereby minimise 
irradiated bowel volume. In an ideal scenario the bladder 
volume would be identical during each treatment fraction. 
This would also minimise organ position variation. There is 
limited data regarding bladder filling variation and its impact 
on target volume coverage in gynaecological cancers.This 
study attempts to quantify the impact of variation in bladder 
filling on target coverage. 
Materials and Methods: 12 patients underwent twice weekly 
cone beam computed tomography (CBCT) scans during 3D 
conformal radiotherapy for gynaecological cancer. 
Retrospective analysis of CBCT's was performed. All were 
planned with a ‘comfortably full bladder’. The standard 
protocol is to drink 600ml of water, 30 minutes before 
scanning or treatment. Actual bladder filling times were 
recorded. The bladder, rectum and clinical target volume 
(CTV) for each patient were contoured on the CBCT using 
Eclipse v11.  Bladder volume and CTV position in relation to 
planning target volume (PTV) was calculated and compared 
with the planning CT. 
Results: 12 patients were analysed; 5 received adjuvant 
radiotherapy for endometrial cancer and 7 received radical 
chemo-radiotherapy for cervical cancer. 130 CBCTs were 
taken and analysed using Offline Review ARIA v11. Significant 
variation in bladder volume is seen throughout treatment and 
between patients despite identical drinking instructions. A 
decrease in bladder volume is seen as treatment progresses 
(approx. 4cc per day). True waiting times vary with only 45% 
of patients fulfilling the planned waiting time +/-5minutes. 
Bladder filling impacts CTV position in cervical cancer due to 
uterine movement. A deviation >150cc from planning volume 
led to the superior anterior uterus extending outside of the 
PTV in all cases, however the CTV remained within the 
treatment field. The largest impact is seen if the bladder 
volume is large (>300mls) at planning. No significant impact 
is seen in post-operative patients.  
Conclusions: Accurate bladder filling minimises daily organ 
position variation and reduces the risk of geographical misses 
in cervical cancer. Clinically significant variation occurs 
despite strict drinking protocols. Systematic reduction 
throughout the treatment course is seen for both cervical and 
endometrial patients. We propose an optimal bladder volume 
range (150-300ml) which should be adhered to at the 
planning stage. We also recommend strict monitoring during 
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treatment for all gynaecological patients using CBCT. 
   
EP-1262   
Four field radiotherapy, IMRT or VMAT in cervix cancer: 
when do the benefits of advanced planning become 
redundant? 
S. Sridharan1, C. Lapuz1, C. Dempsey1, J. Patterson1, L. 
Ponman1, M. Evans1, G. Govindarajulu1, A. Capp1, P. O'Brien1 
1Calvary Mater Newcastle, Department of Radiation 
Oncology, Newcastle NSW, Australia  
 
Purpose/Objective: To analyse 4 field conventional 
radiotherapy (4FRT), intensity modulated radiotherapy (IMRT) 
and volumetric modulated arc therapy (VMAT) in the 
definitive management of cervix cancer and to assess 
whether any dosimetric differences persist with the use of 
larger geometric PTV margins to account for daily variability 
in uterine position. 
Materials and Methods: CT datasets were obtained for 20 
consecutive patients with intact cervix cancer previously 
treated with definitive external beam radiotherapy (with or 
without chemotherapy). The clinical target volume was 
contoured to encompass gross tumour and potential 
microscopic disease including the remaining cervix, uterus, 
upper vagina, parametrium, adnexa and regional lymph 
nodes. The planning target volume (PTV) was generated with 
uterine margins of 1.5cm, 2cm, 2.5cm, 3cm and 4cm used to 
account for internal motion of the uterus, generating five 
PTVs for each patient: PTV1.5, PTV2, PTV2.5, PTV3 and 
PTV4. The rectum, bladder, bowel and femoral heads were 
contoured as organs at risk (OARs). For each patient, a 4FRT 
plan was generated based on conventional field borders 
ensuring coverage of PTV1.5. IMRT and VMAT plans were 
generated for each PTV, except when the PTV extended 
outside 4FRT fields. Prescription dose was 45Gy in 25 
fractions. Plans were evaluated for target coverage, 
conformity, dose homogeneity and dose to OARs. Planning 
time, total monitor units and estimated delivery time were 
also evaluated. 
Results: The median patient age was 56 years (range: 27-84 
years). Stage 1, 2, 3 and 4A disease was seen in 1, 12, 4 and 
3 patients respectively with nodal involvement in 13 patients. 
PTV2.5, PTV3 and PTV4 extended outside the 4FRT fields in 9 
(45%), 13 (65%) and 20 (100%) patients respectively. Target 
coverage was excellent for the 4FRT, IMRT and VMAT plans 
generated, with no significant difference between 
techniques, however, IMRT and VMAT plans were associated 
with a reduction in dose to OARs compared to 4FRT. Mean 
monitor units was lowest with 4FRT, followed by VMAT then 
IMRT.  
Conclusions: IMRT and VMAT are associated with dosimetric 
advantages over 4FRT when margins less than 3cm are used, 
with exceptional target coverage and superior OAR sparing. 
Uterine margins of 3cm or greater commonly resulted in the 
PTV extending outside conventional radiotherapy fields, 
demonstrating no benefit for these advanced planning 
techniques in patients with large variation in uterine 
position. Furthermore, accurate uterine localisation with 
image guidance is critical when considering implementation 
of IMRT or VMAT for cervix cancer treatment. Prospective 
studies are also needed to verify that these newer techniques 
reduce the rates of acute and late toxicities without 
compromising long-term disease control. 
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Purpose/Objective: Evaluate the diagnostic capabilities of 
MRI in the detection of neoplastic lesions of the vagina, as 
well as to optimize the protocol complex MR examination of 
the pelvic organs in clinical use in the planning and 
monitoring of HDR brachytherapy in patients with gynecologic 
cancer with primary or metastatic lesions of the vagina. 
Materials and Methods: With the purpose assess the state of 
the vagina performed 179 MR studies of the pelvic organs in 
108 women with gynecologic cancer, mean age was 58.5 
years. In order to volumetric 3D-planning performed 56 MR 
studies 31 patients with primary and metastatic tumors of 
the vagina treated with brachytherapy in automated complex 
'Microselektron HDR», equipped with isotope 192Ir, using the 
planning system Oncentra Brachy (Nucletron®). Complex MRI 
(Toshiba Vantage Atlas, 1,5 T) pelvic examinations with 
contrast enhancement consisted of native scanning, DWI, 
dynamic contrast enhanced (DCE) examination with 
additional endovaginal MR-compatible applicator 
introduction. All patients previously carried out at different 
times external beam radiotherapy with a total boost dose 46-
60Gr. Re-planning during treatment was performed in 23 
patients. In ultrasonography study to delineate the 
boundaries of the tumor visualized in 62.5% of cases; in CT 
imaging - in 37.5%. For planning we used colpostat diameter 
of 20 mm. 
Results: Neoplastic lesions in vagina were found during 
complex MRI (CMRI) in 58 (51,7%) pts, at lower third - in 5 
(8,6%), as endometrial and vulvar cancer progression, at 
middle third - in 11 (18,9%) pts, at upper third - in 42 
(72,4%), included 18 (31%) pts with vaginal cuff relapse. It 
was revealed as a zone with increasing signal in T2-weighted 
sequence and contrast accumulation in the arterial and 
venous phases. Differential diagnosis with post-radiation 
fibrosis demanded image fusion of T2WI fat sat, DWI and DCE 
with endovaginal MR-suitable applicator, which created 
conditions for better visualization of vaginal wall structure 
and tumor localization because of fold smoothing. In all 
cases, MRI was able to determine the boundaries of the 
tumor process necessary for contouring. At the same time 
25% of patients with symptoms of tumor progression (MRI), 
intimate adhere to vaginal tumors of the bladder or rectum 
involving retro-vesicle, recto-vaginal tissue, demanded 
change of treatment programs, the volume of irradiation, the 
planned total doses, but did not result in rejection of a 
planned rate brachytherapy. According to the dynamic MRI 
performed during the course of radiotherapy, more than 50% 
regression of tumor volume was determined in 50% of 
patients, which in some cases entailed a change in the 
volume of targeted areas.  
Conclusions: CMRI increases the accuracy of primary and 
recurrent vaginal tumors determination and treatment results 
